Roche, Alex­ion ripe for show­down in a race to treat rare CNS dis­or­der

Months af­ter Alex­ion’s $ALXN flag­ship Soliris en­thralled in­vestors with im­pres­sive piv­otal da­ta for pa­tients with neu­romyelitis op­ti­ca spec­trum dis­or­der (NM­SOD), re­searchers at Roche’s Chugai …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER